OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mariam Elshatlawy, Josephina Sampson, K. Clarke, et al.
Molecular Oncology (2023) Vol. 17, Iss. 6, pp. 950-963
Open Access | Times Cited: 30
Showing 26-50 of 30 citing articles:
Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer
Richard Bayliss, Josephina Sampson, Hyun-min Ju, et al.
Research Square (Research Square) (2024)
Open Access
Richard Bayliss, Josephina Sampson, Hyun-min Ju, et al.
Research Square (Research Square) (2024)
Open Access
Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer
Ying Fu, Qing Liu, Xiaohan Wang, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2513-2521
Closed Access
Ying Fu, Qing Liu, Xiaohan Wang, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2513-2521
Closed Access
Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer
Antonella Centonza, Tommaso Mazza, Domenico Trombetta, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 670-670
Open Access
Antonella Centonza, Tommaso Mazza, Domenico Trombetta, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 670-670
Open Access
Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review
Zi‐jun Xu, Xiaofeng Cong, Ziling Liu
Frontiers in Oncology (2024) Vol. 14
Closed Access
Zi‐jun Xu, Xiaofeng Cong, Ziling Liu
Frontiers in Oncology (2024) Vol. 14
Closed Access
Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
Takayuki Suetsugu, Y Masada, Tomoki Kozono, et al.
Respiratory Investigation (2024) Vol. 62, Iss. 6, pp. 1157-1160
Closed Access
Takayuki Suetsugu, Y Masada, Tomoki Kozono, et al.
Respiratory Investigation (2024) Vol. 62, Iss. 6, pp. 1157-1160
Closed Access
Comprehensive profiling of T-cell exhaustion signatures and establishment of a prognostic model in lung adenocarcinoma through integrated RNA-sequencing analysis
Yingying Zhang, Jiaqi Cheng, Pingyan Jin, et al.
Technology and Health Care (2024)
Closed Access
Yingying Zhang, Jiaqi Cheng, Pingyan Jin, et al.
Technology and Health Care (2024)
Closed Access
Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer
Josephina Sampson, Hyun-min Ju, Nan Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 12
Open Access
Josephina Sampson, Hyun-min Ju, Nan Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 12
Open Access
Richard Bayliss, Elżbieta Sarnowska, Sharon Yeoh, et al.
Molecular Oncology (2023) Vol. 17, Iss. 11, pp. 2218-2220
Open Access
